Eledon Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis
Eledon Pharmaceuticals, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Eledon is developing a potentially transformative non-depleting immunosuppressive therapy that addresses critical toxicity shortcomings of current standards, with Phase 3 initiation imminent and multiple indication applications. Analyst sentiment is positive with a "Strong Buy" rating and 12-month price target of $8.5, representing 441% upside potential. The company has demonstrated.
What is Eledon Pharmaceuticals, Inc.'s industry? Eledon Pharmaceuticals, Inc. (eledon.com) operates in Biopharmaceutical/Immunology. AskCyborg classifies Eledon Pharmaceuticals, Inc. under Biopharmaceutical/Immunology in its company registry.
Eledon Pharmaceuticals is a clinical-stage biotechnology company developing immune-modulating therapies, with its lead investigational product being tegoprubart, an anti-CD40L antibody. The company is pursuing transfo...
Cyborg Score thesis
Eledon is developing a potentially transformative non-depleting immunosuppressive therapy that addresses critical toxicity...
Read the full analyst-debate transcript →Get the Latest Eledon Pharmaceuticals, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeEledon Pharmaceuticals, Inc. Overview
Pro stress-test →Eledon Pharmaceuticals is a clinical-stage biotechnology company developing immune-modulating therapies, with its lead investigational product being tegoprubart, an anti-CD40L antibody. The company is pursuing transformative immunosuppressive therapies for organ and cell transplantation, which represent a major unmet medical need affecting millions globally.
Strategic Profile
Pro stress-test →The company's Phase 2 BESTOW trial results showed tegoprubart reduces the metabolic, neurologic and cardiovascular toxicities commonly associated with tacrolimus, positioning it as a potential safer alternative to standard-of-care immunosuppression. Eledon is advancing tegoprubart's programs in kidney transplantation, islet cell transplantation, and xenotransplantation, with Phase 3 development targeted for 2026.
Competitive Landscape
Pro stress-test →Competitive landscape includes larger established players like Gilead, Amgen, Ionis Pharmaceuticals, Genentech, and UCB. Eledon's differentiation lies in its CD40L pathway expertise and non-lymphocyte depleting approach, offering a mechanistically distinct alternative to existing calcineurin inhibitors and other immunosuppressive classes. The company competes in the broader transplant immunosuppression market alongside both small biotech and large pharma competitors.
Industry Context
Eledon Pharmaceuticals, Inc. operates in Biopharmaceutical/Immunology.
Key facts
Founded: 2020 · Headquarters: Irvine, California · Market cap: $148M